Aclaris Therapeutics (STU:8AT) Valuation Rank


STU:8AT Aclaris Therapeutics Inc STU:8AT
27 GF Score
Price €4.83
GF Value €0.39
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Aclaris Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Aclaris Therapeutics Valuation Rank Related Terms

STU:8AT
27GF Score
Aclaris Therapeutics Inc STU:8AT
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aclaris Therapeutics (STU:8AT) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of €4.83 is trading 1139% above its estimated GF Value™ of €0.39. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:8AT:

  • Valuation Rank:
  • GF Value™: €0.39 vs. price of €4.83 (1139% above fair value)
  • GF Score™: 27/100 with 10 warning signs

No single metric tells the full story. See the STU:8AT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aclaris Therapeutics Business Description

Other Exchanges ACRS:USA0H8T:UK
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
27GF Score

Get the complete analysis for STU:8AT

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.83
Price
€0.39
GF Value